In 2013, Amengual and colleagues combined the general SIRTi NAM with all four FDA-approved pan-HDACi and discovered strong synergies, especially in GC-DLBCL cell lines, by inducing Bcl-6 and p53 acetylation [82]. Here, TP53 is linked to diffuse large B-cell lymphoma.